Minimizing the environmental footprint of bioprocesses - Part 2: Evaluation of wastewater, electricity, and air emissions

BioProcess International

Volumn 8, Issue 9, 2010, Pages 36-46

  Junker, Beth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Disposables; Environmental impact; Single use; Sustainability

Indexed keywords

TRACE ELEMENT;

AIR POLLUTION CONTROL; BIOPROCESS; DOWNSTREAM PROCESSING; DRUG INDUSTRY; ELECTRIC CAPACITANCE; PICHIA PASTORIS; REVIEW; WASTE WATER MANAGEMENT;

EID: 78649649955     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (39)

1. Potgieter T, et al. Production of Monoclonal Antibodies By Glycoengineered Pichia pastoris. J. Biotechnol. 139(4) 2009: 318-325.
2. Verslycke T, et al. The Toxicity of Metal Mixtures to the Estuarine Mysid Neomysis integer (Crustacea: Mysidacea) under Changing Salinity. Aquatic Toxicol. 64(3) 2003: 307-315. (Pubitemid 36808794)
3. Wang DIC, et al. Fermentation and Enzyme Technology. John Wiley and Sons: New York, NY, 1979; 94, 95.
4. Riesenberg D. High-Cell-Density Cultivation of Escherichia coli. Curr. Opin. Biotechnol. 2(3) 1991: 380-384.
5. Kalantari N, Ghaffari S. Evaluation of Toxicity of Heavy Metals for Escherichia coli Growth. Iran. J. Environ. Health. Sci. Eng. 5(3) 2008: 173-178.
6. Environmental Protection Agency. Aquatic Life Ambient Freshwater Quality Criteria: Copper. February 2007, US EPA, Office of Water, Office of Science and Technology, Washington, DC, EPA-822-R-07-001.
7. Bartacek J, et al. Cobalt Toxicity in Anaerobic Granular Sludge: Influence of Chemical Speciation. J. Ind. Microbiol. Biotechnol. 35(11) 2008: 1465-1474.
8. Marcellus Shale Wastewater Partnership. Permitting Strategy for High Total Solids (TDS) Wastewater Discharges. Pennsylvania Bureau of Water Standards and Facility Regulation, 11 April 2009.
9. Pizarro SA, et al. Biomanufacturing Process Analytical Technology (PAT) Application for Downstream Processing: Using Dissolved Oxygen As an Indicator of Product Quality for a Protein Refolding Reaction. Biotechnol. Bioeng. 104(2) 2009: 340-351.
10. Lin M-F, et al. Ion Chromatographic Quantification of Cyanate in Urea Solutions: Estimation of the Efficiency of Cyanate Scavengers for Use in Recombinant Protein Manufacturing. J. Chromatogr. B 803(2) 2004: 353-362.
11. Dauchy JW, Waller WT, Piwoni, MD. Acute Toxicity of Cyanate to Daphnia magna. Bull. Environ. Contam. Toxicol. 25(2) 1980: 194-196.
12. Hoffman M. Easing the Bottleneck, Pharm. Technol. 33(5) 2009: 44-50.
13. Moyer AJ, Umberger EJ, Stubbs JJ. Fermentation of Concentrated Solutions of Glucose to Gluconic Acid: Improved Process. Indus. Eng. Chem. 32(10) 1940: 1379-1383.
14. Howe RHL. Complete Biological Treatment of Antibiotic Production Wastes. Biotechnol. Bioeng. 4, 1962: 161-170.
15. Sustarsic M. Wastewater Treatment: Understanding the Activated Sludge Process. Chem. Eng. Progress 105(11) 2009: 26-29.
16. Alahari A. Implementation of Cost-Reduction Strategies for HuMAb Manufacturing Processes. BioProcess Intl. 7(7) 2009: S48-S54.
17. Farid SS. Economic Drivers and Trade-offs in Antibody Purification Processes. BioPharm Intl. 7(3) 2009: S37-S42.
18. Trexler-Schmidt M, et al. Purification Strategies to Process 5 g/L Titers of Monoclonal Antibodies. BioPharm Intl. supplement. March 2009: 8-15.
19. Ho SV, et al. Environmental Considerations in Biologics. Green Chem. 12, 2010: 755-766.
20. Matthews T, et al. An Integrated Approach to Buffer Dilution and Storage. Pharm. Manufacturing 8(4) 2009: 36-39.
21. Patterson BJ. A Closer Look at Automated In-Line Dilution. BioPharm Intl. 22(10) 2009: 52-65.
22. Meyerhoff W. Good Housekeeping: The Art of Contamination Controls. Life Science Leader 1(3) 2009: 14-15.
23. Elvidge S. The "Greening" of Cleanrooms. Life Science Leader 1(5) 2009: 22-23.
24. Thomas P. Big Steps, Shrinking Footprint at Novartis. Pharma. Manufacturing 8(4) 2009: 11.
25. Sinclair A, et al. The Environmental Impact of Disposable Technologies. BioPharm Intl. Supplement, November 2008: 4-15.
26. Leveen L. Single-Use Technology and the Carbon and Water Footprints of Biopharm Manufacturing. Amer. Pharma. Review 12(6) 2009: 72-78.
27. Nidumolu R, Prahalad CK, Rangaswami MR. Why Sustainability Is Now the Key Driver of Innovation. Havard Business Review. September 2009: 57-64.
28. Jagschies, G. State of Bioproduction, Cheaper Ways or Smarter Solutions? BioProcess Intl. 6(10) 2008: 96.
29. Guidager, N. Next-Generation Facilities for Monoclonal Antibody Production. Pharma. Technol. 33(7) 2009: S68-S73.
30. Panda, AK. Bioprocessing of Therapeutic Proteins from the Inclusion Bodies of Escherichia coli. Adv. Biochem. Eng.Biotechnol. 85, 2003: 43-93.
31. Hacker DL, DeJesus M, Wurm FM. 25 Years of Recombinant Proteins from Reactor-Grown Cells: Where Do We Go from Here? Biotechnol. Advances 27, 2009: 1023-1027.
32. Anicetti V. Biopharmaceutical Processes: A Glance into the 21st Century. BioProcess Intl 7(7) 2009: S4-S11.
33. Zhou J, et al. Implementation of Advanced Technologies in Commercial Monoclonal Antibody Production. Biotech. J. 3(9-10) 2008: 1185-1200.
34. Jenck JF, Agterberg F, Droescher MJ. Projects and Processes for a Sustainable Chemical Industry: A Review of Achievements and Prospects. Green Chem. 6, 2004: 544-556.
35. Farid SS. Economic Drivers and Trade-Offs in Antibody Purification Processes. BioPharm Intl. 7(3) 2009: S37-S42.
36. Gurramkonda C, et al. Simple High-Cell Density Fed-Batch Technique for High-Level Recombinant Protein Production with Pichia pastoris: Application to Intracellular Production of Hepatitis B Surface Antigen. Microbial Cell Factories 8(1) 2009: 13-20.
37. Hang H, et al. A Simple Fermentation Strategy for High-Level Production of Recombinant Phytase by Pichia pastoris Using Glucose as the Growth Substrate. Enzyme Microbial Technol. 44(4) 2009: 185-188.
38. George H, Herber W. Culture Medium for Saccharomyces cerevisiae. US Patent 5795771, 1998.
39. Wegner, EH. Biochemical Conversions by Yeast Fermentation at High Cell Densities. US Patent 4,617,274, 1986.